Foundayo and Pregnancy: Is It Safe? What to Know Before, During & After

If you are pregnant, planning to become pregnant, or breastfeeding, you need to know that Foundayo (orforglipron) is not safe to use during pregnancy. The FDA prescribing information clearly states that Foundayo "may cause fetal harm" based on animal reproduction studies. This guide covers everything you need to know about Foundayo and reproductive health — including pregnancy risks, breastfeeding concerns, fertility data, and what to do if you become pregnant while taking the medication.

Is Foundayo Safe During Pregnancy?

No. Foundayo is not safe during pregnancy. The FDA label carries a clear warning that orforglipron may cause fetal harm. This warning is based on animal studies in which orforglipron was administered during pregnancy at clinically relevant doses. Those studies showed adverse developmental effects on the fetus, including growth restriction and structural abnormalities.

There are no adequate and well-controlled human studies of Foundayo use during pregnancy. Because of the animal data and the absence of human safety data, the FDA recommends that Foundayo should be discontinued immediately when pregnancy is recognized.

This is consistent with recommendations for other GLP-1 receptor agonists. Weight loss medications in general are not recommended during pregnancy, because intentional weight loss offers no benefit to a pregnant woman and may result in fetal harm.

What to Do If You Become Pregnant on Foundayo

If you discover you are pregnant while taking Foundayo, take these steps immediately:

• Stop taking Foundayo. Do not wait for your next appointment — discontinue the medication right away.
• Contact your healthcare provider. Inform them that you were taking orforglipron and discuss prenatal care planning.
• Enroll in the Pregnancy Exposure Registry. Eli Lilly has established a registry specifically to monitor outcomes in women who are exposed to Foundayo during pregnancy.

The Foundayo Pregnancy Exposure Registry

Eli Lilly maintains a Pregnancy Exposure Registry for women who become pregnant while taking Foundayo or who were recently exposed to the drug before becoming pregnant. The registry collects data on pregnancy outcomes to help inform future safety guidance.

Healthcare providers and patients can contact the registry at:

• Phone: 1-800-LillyRx (1-800-545-5979)

Enrollment is voluntary but strongly encouraged. The more data available, the better physicians can counsel future patients about the risks of inadvertent exposure during early pregnancy.

Planning a Pregnancy After Foundayo

If you are taking Foundayo and planning to become pregnant, discuss timing with your healthcare provider. There is no specific FDA guidance on how long to wait after stopping Foundayo before conceiving, but there are several factors to consider:

• Half-life: Orforglipron is a small-molecule GLP-1 agonist with a relatively short half-life compared to injectable GLP-1 medications like semaglutide (which has a half-life of about 7 days). This means orforglipron clears the body faster after discontinuation — likely within days rather than weeks.
• Washout period: Most clinicians recommend waiting at least 2 months after stopping any GLP-1 medication before actively trying to conceive, to ensure the drug has fully cleared. However, your provider may recommend a different timeline based on your individual situation.
• Nutritional readiness: If you have been on Foundayo for weight loss, make sure you are nutritionally prepared for pregnancy. Rapid weight loss can deplete nutrient stores (folate, iron, vitamin D) that are critical for fetal development. Consider preconception bloodwork and prenatal vitamins.

Breastfeeding and Foundayo

Foundayo is not recommended during breastfeeding. Here is what the data shows:

• In animal studies, orforglipron was detected in rat milk at concentrations approximately 3 times higher than in maternal plasma.
• There are no human data on whether orforglipron passes into human breast milk.
• Given the animal findings, it is considered likely that orforglipron would be present in human milk.
• The potential effects of orforglipron on a breastfed infant are unknown.

Because of these uncertainties, the FDA advises that breastfeeding women should either discontinue Foundayo or discontinue breastfeeding, taking into account the importance of the drug to the mother. This is a decision best made with your healthcare provider, weighing the benefits of continued breastfeeding against the mother's need for weight management treatment.

Weight loss during breastfeeding — whether from medication or caloric restriction — can reduce milk supply and alter the nutritional composition of breast milk. This is another reason the medical community generally recommends waiting until after weaning to resume weight loss medications.

Does Foundayo Affect Fertility?

Based on available animal data, orforglipron does not appear to affect male or female fertility. In rat fertility studies conducted at doses producing systemic exposures up to 19 times the maximum recommended human dose, no adverse effects on reproductive function were observed. This includes:

• No effects on sperm count, motility, or morphology in males
• No effects on estrous cycling, ovulation, or implantation in females
• No effects on mating behavior or fertility indices

However, it is important to note that weight loss itself can affect fertility — both positively and negatively. For women with obesity-related anovulation or PCOS, weight loss may actually improve fertility by restoring ovulation. This means some women on Foundayo may become more fertile as they lose weight, making contraception even more important during treatment.

Contraception Requirements for Women of Reproductive Potential

The FDA label requires that women of reproductive potential use effective contraception during Foundayo treatment. Critically, Foundayo also reduces the effectiveness of oral hormonal contraceptives by delaying gastric emptying and reducing absorption. This means:

• If you are on the pill, you need to either switch to a non-oral method or add a barrier method (condoms) for 30 days after starting Foundayo and after each dose increase.
• Non-oral methods — IUDs, implants, patches, rings, injectables — are not affected by Foundayo and are strongly preferred.

For a complete breakdown of which contraceptive methods are safe during Foundayo therapy, see our detailed guide: Foundayo and Birth Control.

Key Takeaways

• Foundayo is not safe during pregnancy — discontinue immediately if pregnancy is recognized.
• Breastfeeding is not recommended while taking Foundayo.
• Orforglipron does not appear to affect fertility, but weight loss may improve fertility in some women — making unintended pregnancy more likely without contraception.
• Oral contraceptives are less effective during Foundayo therapy — use a non-oral method.
• Contact the Pregnancy Exposure Registry at 1-800-LillyRx (1-800-545-5979) if you become pregnant.
• Plan ahead: discuss stopping Foundayo and nutritional preparation with your provider before trying to conceive.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication, especially in the context of pregnancy or breastfeeding. The information presented reflects current FDA labeling and available clinical data. Individual circumstances may vary.